




PHARMACEUTICAL 2023

DURECT CORP
Rank 279 of 446





PHARMACEUTICAL 2023

DURECT CORP
Rank 279 of 446



The relative strengths and weaknesses of DURECT CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DURECT CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 26% points. The greatest weakness of DURECT CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 20%, being 23% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	51,394
Cost of Goods Sold	1,588
Intangible Assets	6,169
Liabilities, Current	34,004
Liabilities, Non-Current	0
Other Assets	2,349
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-251
Other Revenues	19,283
Property and Equipment	188
Research and Development	36,862
Selling, General and Administrative Expense	15,915

Output Variable	Value in 1000 USD
Assets	60,100
Liabilities	34,004
Expenses	54,365
Revenues	19,283
Stockholders Equity	26,096
Net Income	-35,333
Comprehensive Net Income	-35,334
Economic Capital Ratio	20%